Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006013 · ClinicalTrials.gov registry record · Phase 2
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT00006013 is a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 21 participants, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00006013, a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.
Conditions Studied
Interventions
- DRUG semaxanib
Study Locations (4)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Illinois
- University of Chicago Cancer Research Center - Chicago
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2000-06 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006013
The ClinicalTrials.gov registry entry for NCT00006013 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (97% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which semaxanib is the first listed.
NCT00006013 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00006013 about?
NCT00006013 is a clinical study titled "SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma". RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.
What is the current status of trial NCT00006013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2000-06. Estimated completion is 2003-01.
What conditions does trial NCT00006013 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00006013?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00006013?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006013 being conducted?
This trial has 4 study locations across Florida, Illinois, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
COMPLETED · Phase 2
-
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
COMPLETED · Phase 2
-
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
COMPLETED · Phase 2
-
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
COMPLETED · Phase 2
-
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 2
-
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.